


## TLX591-CDx (Branded as *illumet*<sup>TM</sup> in the United States) Sales Note to Accompany Appendix 4C

Melbourne (Australia) – 31 July 2019. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Group”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), today provides a sales update for the TLX591-CDx (<sup>68</sup>Ga-PSMA-11) kit, branded in the United States as *illumet*<sup>TM</sup>.

TLX591-CDx (*illumet*<sup>TM</sup>) is commercially available as a “cold kit” (“Kit”) for the preparation of <sup>68</sup>Ga-PSMA-11 for the imaging of metastatic prostate cancer. The Kit is available for use on a limited basis as an investigational product for an authorised clinical trial (US) on a named patient basis (EU/UK), Special Access Scheme (Australia) or compassionate use (RoW).

**TLX591-CDx has not received a marketing authorisation in any jurisdiction.**


In the second quarter (Apr-Jun) the Group booked orders of A\$1.2m with A\$792,000 of revenue recognised and A\$942,000 cash reported in the Group’s Appendix 4C. The difference between revenue and cash is attributable to payment terms on invoices (typically 60 days).




This represented a 30% increase in sales of Kits (and related revenues) from the previous quarter. The number of Kits deployed on a monthly basis has grown from approximately 400 units/month at end-Q1 to ~800 units/month at end-Q2. However, the proportion of Kits deployed that can be attributed to clinical collaborations and samples provided to prospective clinical sites for customer evaluation (business development) has also increased to 24% of total deployed units.

---

A sales breakdown is illustrated below:



Pricing for kits has remained stable quarter-on-quarter with EU customers typically paying 80% of US list pricing (~\$1,000) and RoW customers paying around 75% of US list pricing.



Telix CEO Dr. Christian Behrenbruch stated, “Although we are not yet forecasting sales of the TLX591-CDx (*illumet*<sup>TM</sup>) kit as it has not received a marketing authorisation in key commercial territories, this early revenue through placement of the Kit clearly demonstrates the clinical interest in the product. Our prostate imaging technology is now in regular use at over a hundred tertiary-referral cancer centres around globe as part of clinical studies and named-patient use. This early commercial traction has been enormously beneficial to Telix in terms of validating the product and roll-out preparation for commercialisation next year.”

### **About Telix Pharmaceuticals**

Telix Pharmaceuticals Limited (“Telix”) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in

---

renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit [www.telixpharma.com](http://www.telixpharma.com).

\*\*\*

### **Telix Corporate Contact**

Dr Christian Behrenbruch  
Telix Pharmaceuticals Limited  
CEO  
Email: [chris@telixpharma.com](mailto:chris@telixpharma.com)

### **Telix Investor Relations (US)**

Lisa Wilson  
In-Site Communications  
Tel: +1 212 452 2793  
Email: [lwilson@insitecony.com](mailto:lwilson@insitecony.com)

### Important Information

*This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the products described in this release have obtained a marketing authorisation in any jurisdiction.*